Feasibility of Metformin and Omega-3 Fatty Acids combination evaluated in early-stage breast cancer survivors

Early-stage breast cancer survivors often seek adjuvant strategies to prevent recurrence and improve long-term health. Current standard-of-care focuses on surgery, radiation, chemotherapy, and hormone therapy, but lifestyle interventions and repurposed drugs like metformin are gaining interest for their potential anti-cancer effects. Metformin, a common diabetes drug, has shown promise in modulating cancer cell metabolism and proliferation, while omega-3 fatty acids are recognized for their anti-inflammatory and immunomodulatory properties. This study explores the feasibility of combining these agents to leverage their synergistic benefits in a post-treatment setting.

This study aims to determine the feasibility of administering a combination of Metformin and omega-3 fatty acids for one year to women with a history of early-stage breast cancer. The protocol involves evaluating changes in breast tissue, blood biomarkers, and mammographic findings. The primary endpoints include assessing patient tolerability, adherence to the regimen, and preliminary biological responses to the combined intervention. This is a single-arm feasibility study, not designed for efficacy.